Biogen Inc.
BIIBLast close · Oct 16, 2026232.65−2.70 (−1.15%)
Market cap$34.4B
12 firms' latest targets, last 90 days: median $249.50 ($175.00–$300.00), 7% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-12 | BMO Capital | $220.00 | ▲ 12% | -5% |
| 2026-10-09 | UBS | $270.00 | ▲ 13% | +16% |
| 2026-10-08 | RBC Capital | $256.00 | ▼ 2% | +10% |
| 2026-09-10 | Stifel | $242.00 | — | +4% |
| 2026-09-10 | HSBC | $175.00 | ▲ 11% | -25% |
| 2026-09-03 | Piper Sandler | $245.00 | ▲ 9% | +5% |
| 2026-08-13 | Wolfe Research | $300.00 | ▲ 30% | +29% |
| 2026-07-30 | Morgan Stanley | $231.00 | ▲ 4% | -1% |
| 2026-07-30 | H.C. Wainwright | $251.00 | ▲ 10% | +8% |
| 2026-07-30 | Canaccord Genuity | $248.00 | ▲ 8% | +7% |
| 2026-07-29 | Oppenheimer | $300.00 | ▲ 33% | +29% |
| 2026-07-21 | Guggenheim | $280.00 | ▲ 8% | +20% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $9.8B | -3% | $7.97 | -62% | est. $9.9B-1% | est. $14.99 | 29 |
| 2024reported | $9.7B | -2% | $11.18 | +40% | est. $9.6B+0% | est. $16.38 | 30 |
| 2025reported | $9.9B | +2% | $8.79 | -21% | est. $9.8B+1% | est. $14.94 | 30 |
| 2026 | $10.5B | +6% | $12.42 | -17% | $10.1B–$10.6B | $10.80–$15.41 | 25 |
| 2027 | $10.7B | +2% | $16.50 | +33% | $10.1B–$11.2B | $11.54–$19.71 | 27 |
| 2028 | $11.0B | +3% | $18.62 | +13% | $10.1B–$11.7B | $13.46–$25.24 | 27 |
| 2029 | $11.1B | +1% | $20.45 | +10% | $10.5B–$11.5B | $19.02–$21.40 | 13 |
| 2030 | $11.4B | +2% | $20.45 | +0% | $10.8B–$11.8B | $19.02–$21.40 | 13 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.